Full-Time

Senior Director

Posted on 11/23/2025

Integer Holdings Corporation

Integer Holdings Corporation

1,001-5,000 employees

Medical device CDMO for cardiac devices

Compensation Overview

$180.8k - $265.1k/yr

+ Stock Awards

Corfu, NY, USA

In Person

Category
Operations & Logistics (2)
,
Requirements
  • Technical or business Bachelor's degree, with Master’s degree(s) in business or technical field desired.
Responsibilities
  • Health, Safety, and Environmental Responsibility: Ensure the site adheres to all health, safety, and environmental regulations, maintaining a safe workplace for all employees.
  • Continuously improve the safety profile of the site by promoting a culture of safety through training, risk assessments, and the implementation of corrective actions as needed.
  • Compliance and Quality Assurance: Adhere to Integer Core Value and all safety, environmental, security and quality requirements including, but not limited to: Quality Management Systems (QMS), Safety, Environmental and Security Management Systems, U.S. Food and Drug Administration (FDA) regulations, company policies and operating procedures, and other regulatory requirements.
  • Ensure manufacturing operations comply with all relevant regulatory standards, including FDA cGMP, ISO 13485-2003, and other industry-specific regulations.
  • Adherence to the quality management systems (QMS), ensuring products meet the highest quality standards.
  • Support the site through internal and external audits, addressing any findings and implementing corrective actions as necessary.
  • Operational Leadership: Lead and develop Plant Leadership Team in alignment with long-term growth strategy of the site.
  • Oversee the day-to-day operations of the manufacturing facility, ensuring the efficient production of medical devices and components while maintaining a safe and compliant work environment.
  • Drive key performance indicators (KPIs) such as safety, quality, delivery, inventory, productivity/cost. Regularly report on site performance, challenges, and progress toward goals to senior leadership and stakeholders.
  • Ensure adherence to production schedules, product specifications, and customer requirements.
  • Create, drive, and lead a culture of continuous improvement including methods and tools, behaviors and problem solving consistent with the LEAN principles established by Integer to improve production efficiency, quality, and cost control.
  • Engage and coordinate the role of enterprise functions in the site agenda.
  • Site Execution Plan: Develop and execute the site plan in alignment with the business strategy, and ensure it is incorporated in the site Hoshin plan
  • Provide input to the long-range Plan (LRP) for the Product Line and ensure there are capacity, capital, and footprint plans in place to support the growth.
  • Develop new manufacturing technologies and automation needed to stay globally competitive and grow the site
  • Work collaboratively with the Growth Teams and Commercial team to target, prospect, assess, and close new business that aligns with site capabilities
  • Engineering: Ensure new product introduction activities at the site are completed on time, on budget, at cost, and in full.
  • Oversee and support sustaining engineering to ensure maintenance of facilities and improvement of manufacturing processes
  • Continuously drive process improvements and automation, inclusive of new manufacturing technology development.
  • Organizational Development/Engagement: Lead and develop a cross-functional Plant Leadership Team, both direct and indirect reports, collaborating closely with matrix managers and enterprise leaders where appropriate.
  • Conduct regular performance and talent reviews, provide coaching, and ensure team members are positioned for career growth opportunities.
  • Lead people in adherence to Integer values, create an environment and culture where all associates are able to contribute to their full potential.
  • Conduct regular site wide communication to both DL and IDL associates. Lead efforts to drive an engaged workforce.
  • Creates an organizational development plan based on Talent reviews and site’s needs.
  • Ensure successors are identified and developed for key roles.
  • Budget and Financial Management: Responsible for the P&L and accountable for achieving profitability (GM/AOI) growth targets and maximum return on invested capital.
  • Drive cost improvement, to meet or exceed profitability targets
  • Using SIOP and sound business practices, develop annual financial plans with the FP&A function to support continuous growth and cost improvements. This includes developing justifications and plans for investments in training, staffing, and capital equipment. Provide Monthly Operational performance summaries inclusive of a 12-month rolling financial forecast to achieve GM/AOI performance to changing revenues and product mix.
  • Support Customer Operations activities within the facility including scheduling, quoting, and customer service.
  • Participate in business development activities to develop customer relationships and build pipeline.
  • Coordinate business case, risk and technical assessments, and customer communication in partnership with the commercial team to develop scenario(s) with optimum time to profit and minimum disruption to the existing business.
  • Responsible for accurately forecasting Quarterly / Annual financial results and lead the site’s execution to achieve them.
Integer Holdings Corporation

Integer Holdings Corporation

View

Integer Holdings Corporation is a large medical device contract development and manufacturing organization (CDMO) that supports medical device makers in cardiac rhythm management, neuromodulation, and cardiovascular markets. It provides end-to-end services from design support to manufacturing, delivering components and finished subsystems such as implants, housings, electrodes, and batteries through its Greatbatch Medical, Lake Region Medical, and Electrochem brands. The company differentiates itself by its scale, breadth of capabilities across multiple medical specialties, established brand portfolio, and global manufacturing footprint that enable reliable, integrated supply. Its goal is to improve patients’ lives worldwide by helping customers bring safe and effective medical technologies to market.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Wilmington, Delaware

Founded

1940

Simplify Jobs

Simplify's Take

What believers are saying

  • Board initiated strategic review on April 30, 2026, exploring sale options.
  • Irenic Capital acquired $99M stake in Q4 2025 as top holding.
  • $200M share repurchase authorization signals management confidence in valuation.

What critics are saying

  • Class action lawsuits by Pomerantz and Bleichmar drain cash via settlements by Q4 2026.
  • Three new products cause 3-4% headwind, slashing H2 2026 margins.
  • Irenic activism forces sale at depressed valuation below $93 target in 12 months.

What makes Integer Holdings Corporation unique

  • Integer specializes in contract manufacturing for Cardio & Vascular medical devices.
  • Organic revenue grew 1.3% in Q1 2026 despite flat overall sales.
  • Robust pipeline targets above-market growth by 200 basis points in 2027.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

Adoption Assistance

Parental Leave

401(k) Company Match

401(k) Retirement Plan

Paid Vacation

Paid Holidays

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Yahoo Finance
Mar 24th, 2026
Integer VP sells $70K in shares as stock drops 28% in a year

Integer Holdings Corporation shares fell 28% following an insider sale disclosure. Tom Thomas, the company's vice president and corporate controller, sold 825 shares of common stock in an open-market transaction on 13 March 2026, according to an SEC Form 4 filing. The transaction was valued at $70,000 at a reported price of $85 per share. The sale represented 15.85% of Thomas's direct holdings at the time. Following the transaction, Thomas holds 4,380 shares worth approximately $364,000. This marks Thomas's third open-market sale since 2018, following previous sales of 884 shares in November and 1,500 shares in April. Integer Holdings manufactures medical devices and components, generating $1.85 billion in trailing twelve-month revenue.

Yahoo Finance
Feb 26th, 2026
Integer Holdings Q4 earnings beat forecasts on strong Cardio & Vascular demand

Integer Holdings, a medical device manufacturer, reported fourth quarter revenue of $472.1 million and adjusted earnings per share of $1.76, both exceeding analyst expectations. The company posted 5% year-on-year revenue growth, driven by strong performance in its Cardio & Vascular segment. CEO Peyman Khales attributed $30 million in operational improvements to higher sales volume, manufacturing efficiencies and expense management. The company guided adjusted earnings per share of $6.54 for 2026, beating analyst estimates by 3.8%. During the earnings call, analysts questioned the narrowing of organic sales guidance, first quarter margin compression and the company's path to above-market growth in 2027. Management emphasised collaborative customer planning and reaffirmed its current strategy despite activist investor involvement.

Intellectia.AI
Feb 23rd, 2026
Irenic Capital takes $99M stake in Integer Holdings as medical device firm posts 8% sales growth

Irenic Capital Management has acquired a $99.11 million stake in Integer Holdings, purchasing 1,263,663 shares in Q4 2026. The position represents 13.7% of Irenic's assets under management, making it the fund's largest disclosed equity holding. Integer Holdings, a medical device company, achieved 8% sales growth in 2025, reaching $1.85 billion in revenue, with adjusted earnings per share rising 21% to $6.40. The company reported fourth-quarter sales of $472 million and net income of $62 million, up 22% year-over-year. Management projects 2026 adjusted earnings per share between $6.29 and $6.78, with plans to achieve organic growth exceeding market rates by 200 basis points in 2027. Benchmark analyst Robert Wasserman upgraded the stock from hold to buy with a $95 price target.

Yahoo Finance
Feb 23rd, 2026
Integer posts 21% adjusted EPS growth but warns of H1 2026 headwinds from slower product adoption

Integer Holdings reported strong 2025 results with sales up 8% and adjusted earnings per share rising 21% to $6.40, alongside margin expansion and $105 million in free cash flow. The company returned capital through a $50 million share repurchase and announced an additional $50 million accelerated share repurchase programme. However, management warned that three newer products representing approximately 6% of 2025 sales are experiencing slower-than-expected adoption, creating a 3%–4% headwind for 2026. The company expects flat-to-slightly-down sales and a 200–250 basis point hit to first-quarter operating margin, with recovery and margin expansion anticipated in the second half. Integer maintained its 2026 midpoint guidance, with year-end net debt expected at $1.17–1.19 billion and net leverage remaining at 3.0 times adjusted EBITDA.

Yahoo Finance
Feb 19th, 2026
Integer faces 2026 headwinds from delayed product launches despite $200M buyback and robust pipeline

Integer Holdings, a medical device contract manufacturing organisation, reported fourth-quarter sales of $472 million, up 5% year-over-year, with adjusted earnings per share at the high end of its October guidance range. For the full year 2025, sales increased 8% on a reported basis and over 6% organically, whilst adjusted operating income rose 13%. The company issued 2026 guidance expecting reported sales to be down 1% to up 1%, with a 3% to 4% headwind from three new products facing lower-than-expected market adoption. However, Integer's underlying business is expected to grow 4% to 6%, in line with the market. Integer repurchased $50 million of shares in Q4 and announced plans for an additional $50 million accelerated share repurchase programme under its $200 million authorisation.

INACTIVE